MedTrace Logo

Sanofi Pasteur Quadrivalent Intradermal Influenza Vaccine Pregnancy Registry

NCT02554409 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 87

Last updated 2020-02-12

No results posted yet for this study

Summary

The Sanofi Pasteur Fluzone Intradermal Quadrivalent vaccine (Fluzone QIV-ID) Pregnancy Registry will be a prospectively recruited pregnancy surveillance program designed to collect to collect and analyze information on vaccine exposures, pregnancy outcomes, and fetal and offspring outcomes on pregnant women exposed to Fluzone QIV-ID vaccine.

Conditions

Interventions

BIOLOGICAL

Quadrivalent Intradermal Influenza Vaccine (QIV)

No Intervention as part of this protocol

Sponsors & Collaborators

  • Sanofi Pasteur, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Product Safety Officer · Sanofi Pasteur Inc.

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2015-10-13
Primary Completion
2019-04-30
Completion
2019-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02554409 on ClinicalTrials.gov